---
document_datetime: 2025-11-17 15:41:40
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/odomzo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: odomzo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1861901
conversion_datetime: 2025-12-28 10:23:36.252892
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Odomzo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 02/10/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000268112   | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 5.3, and 6.6 of the SmPC in order to update non-clinical safety information on carcinogenicity based on final results from studies 8371102, and BRT_17_037G_TN; this is a 26-Week Oral Gavage Carcinogenicity Study with LDE225 in Transgenic Mice (RasH2 [001178-T (hemizigous), CByB6F1-Tg(HRAS)2Jic]), and a 104-Week Carcinogenicity Study of LDE225 in Wistar Rats by Oral Route, respectively. Sections 5.3 and 6.6 of the SmPC were also updated to include a statement on risk to the environment in line with the commitment following EMEA/H/C/002839/IB/0056. The RMP version 8.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to introduce editorial changes, and to bring the PI in line with the latest QRD template.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|